MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
Galecto Accounts Payables 2011-2026 | GLTO
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Galecto
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 444 K | 377 K | 1.7 M | 3.35 M | 1.53 M | 2.85 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.35 M | 377 K | 1.71 M |
Quarterly Accounts Payables Galecto
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 520 K | 756 K | 354 K | 377 K | 503 K | 724 K | 1.66 M | 1.7 M | 4.48 M | 5.56 M | 3.55 M | 3.35 M | 1.91 M | - | 3.22 M | 1.53 M | 1.98 M | 1.58 M | 1.78 M | 2.85 M | 2.85 M | 2.85 M | 2.85 M | 3.33 M | 3.33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.56 M | 354 K | 2.23 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | USA |
|
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
AgeX Therapeutics
AGE
|
1.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
611 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
3.98 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
2.91 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | USA |
 |
Avenue Therapeutics
ATXI
|
78 K | - | -52.27 % | $ 4.45 M | USA |
 |
AVROBIO
AVRO
|
27 K | - | 1083.1 % | $ 745 M | USA |
 |
Axcella Health
AXLA
|
4.71 M | - | -16.42 % | $ 249 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M |  Israel |
 |
BeiGene, Ltd.
BGNE
|
479 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
18.5 M | - | - | $ 546 M | USA |
 |
Allakos
ALLK
|
1.76 M | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | USA |
 |
Atreca
BCEL
|
1.74 M | - | -11.76 % | $ 5.79 M | USA |
 |
CASI Pharmaceuticals
CASI
|
4.79 M | - | - | $ 35.4 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
ChemoCentryx
CCXI
|
6.75 M | - | - | $ 3.74 B | USA |
 |
AlloVir
ALVR
|
1.28 M | - | 4.14 % | $ 49.1 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
1.23 M | - | -74.18 % | $ 955 K | USA |
 |
Chimerix
CMRX
|
2.85 M | - | - | $ 756 M | USA |
 |
AbbVie
ABBV
|
3.59 B | $ 208.7 | -0.07 % | $ 369 B | USA |
 |
Calithera Biosciences
CALA
|
3.65 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
3.22 M | - | -3.03 % | $ 260 M | USA |